Abstract:Xiao-Yang Xu, &ast Ze Wang, &ast Chen-You Liu, &ast Hao-Dong Wu, Ze-Xin Hu, Yu-Ying Lin, Shuai Zhang, Jian Shen, Bin-Yan Zhong, Xiao-Li Zhu Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiao-Li Zhu, Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Street, Suzhou, 215006, People's Republic of China, Email Objective: To explore changing trends in circulating immune indicators of hepatocellular carcinoma (HCC) undergoing TACE plus immune checkpoint inhibitors (ICIs) and anti-VEGF antibodies/TKIs and to elucidate the relationship between immune response and tumor prognosis. Materials: This single-center retrospective study included patients with unresectable HCC undergoing TACE plus ICIs and anti-VEGF antibodies/TKIs from March 11, 2019, to February 15, 2024. Peripheral blood samples were collected at baseline and every cycle, from which blood cell counts and immune indicators were analyzed. The primary outcome was the objective response rate (ORR) at the first evaluation. According to the first evaluation based on mRECIST, patients were classified into PD, SD, and OR groups for analysis. Further subgroup analysis was performed on the OR group based on whether experiencing progression after the first evaluation. Lymphocyte subsets were measured by flow cytometry. Immunoglobulins were measured using the immune turbidimetric method. The neutrophil-to-lymphocyte ratio (NLR) was measured by the complete blood count. Simple linear regression was employed to examine the dynamic trends. Results: A total of 63 patients were enrolled, with an ORR of 55.6% and a disease control rate (DCR) of 87.3% at the first evaluation. The median overall survival (mOS) was 27.5 months (95% CI: 22.5– 32.5 months). In the OR group (n=35), more active immune responses, expressed in a decrease in CD3 − CD19 + ( p =0.004), CFB ( p =0.027), NLR ( p < 0.001) and an increase in Ig λ ( p =0.010), Ig κ ( p =0.037), Ig A ( p =0.005), Ig G ( p =0.006), were related to better prognosis, while similar patterns seen in the OR-nPD subgroup. Concurrently, no significant differences were noted in the PD group (n=8). Conclusion: The combination therapy may modify the tumor microenvironment of HCC. Changing trends in circulating immune indicators and NLR can serve as potential biomarkers for predicting tumor response and guiding clinical treatment. Keywords: immune indicator, TACE, immune checkpoint inhibitors, tyrosine kinase inhibitors, tumor microenvironment Hepatocellular carcinoma (HCC) is characterized by high incidence and mortality rates, with approximately half of the global new cases and deaths occurring in China each year. 1 HCC often presents insidiously, and over 80% of patients are diagnosed at an advanced stage, resulting in a low curative resection rate and poor prognosis. 2 According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the recommended standard treatment for patients with intermediate HCC and is also widely used for advanced HCC. 3,4 TACE works by embolizing the tumor blood supply, leading to tumor ischemia and hypoxia, thereby inhibiting tumor progression while chemotherapy drugs can be administered locally and accurately. 5 However, the resultant hypoxic environment can stimulate angiogenic pathways, such as vascular endothelial growth factor (VEGF), reducing the number and function of immune cells. Combining immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) can improve the hypoxic and immunosuppressive tumor microenvironment (TME) and inhibit tumor angiogenesis. 6 Anti-VEGF plays its role as an anti-vascular, anti-angiogenic, or anti-permeability factor in preventing tumor growth and metastasis. 7 Therefore, the combination therapy of TACE plus ICIs and anti-VEGF antibodies/TKIs holds the potential for further improving the efficacy of treatment for unresectable HCC (uHCC). 8,9 Some studies, such as EMERALD-1, CHANCE001, and CHANCE2201, have further demonstrated that this combination therapy significantly improves the prognosis of patients with uHCC. 10–12 The liver, being an immune-privileged organ, often exhibits a lack or even absence of tumor-infiltrating lymphocytes in both the HCC tumor nests and surrounding stroma, making it difficult to generate functional tumor-specific T cells and thus an effective anti-tumor immune response. 13–15< -Abstract Truncated-

HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma

Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma.

Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma Following Transarterial Chemoembolization: is It Helpful for Tumor Response?

Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy

Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials.

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.

Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma

1001P PD1midKLRG1+Tbethigh Effector Memory T in the Peripheral Blood Correlates with Tumor Response to Combined Therapy with Lenvatinib and Anti-Pd-1 Antibodies in Unresectable Hepatocellular Carcinoma

Quantitative Parameters of Contrast-Enhanced Ultrasound Predicting the Response to Combined Immune Checkpoint Inhibitor and Anti-angiogenesis Therapies for Unresectable Hepatocellular Carcinoma

Immune Indicator Changes in Hepatocellular Carcinoma Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs: A Prognostic Biomarker Analysis

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular Carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

Enhanced Rim On Mdct Of Colorectal Liver Metastases: Assessment Of Ability To Predict Progression-Free Survival And Response To Bevacizumab-Based Chemotherapy

Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer

Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).

Rim enhancement on hepatobiliary phase of pre-treatment 3.0 T MRI: A potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX

CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils